ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.60
-0.34%
US Tech 100
17,650.00
0.05%
S&P 500
5,222.68
0.16%
US Dollar vs CAD
1.36775
0.00%
Bitcoin
60,978.89
0.30%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Kazia Therapeutics Ltd (KZIA)

  7. Kazia Therapeutics Ltd (KZIA) News

KZIA

Kazia Therapeutics (KZIA)

Kazia Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KZIA
DateTimeSourceHeadlineSymbolCompany
05/01/20247:45AMPR Newswire (US)KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSNASDAQ:KZIAKazia Therapeutics Ltd
03/21/20247:52AMPR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesNASDAQ:KZIAKazia Therapeutics Ltd
03/13/20247:00AMPR Newswire (US)Kazia announces presentation of new data at AACR Annual MeetingNASDAQ:KZIAKazia Therapeutics Ltd
02/21/20243:19PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
02/21/20248:19AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
02/21/20246:30AMPR Newswire (US)Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointNASDAQ:KZIAKazia Therapeutics Ltd
02/14/20242:41PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KZIAKazia Therapeutics Ltd
02/12/20245:35PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KZIAKazia Therapeutics Ltd
02/05/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
02/05/20243:19PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
01/18/20243:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
01/18/20246:30AMPR Newswire (US)KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSNASDAQ:KZIAKazia Therapeutics Ltd
01/12/20243:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
12/25/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
12/15/20234:26PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:KZIAKazia Therapeutics Ltd
12/15/20233:49PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:KZIAKazia Therapeutics Ltd
12/06/20237:31AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
12/05/20235:02PMPR Newswire (US)Kazia Therapeutics Announces Closing of $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
12/04/20233:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KZIAKazia Therapeutics Ltd
12/01/20237:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
12/01/20237:00AMPR Newswire (US)Kazia Therapeutics Announces $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
11/29/20233:19PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
11/29/20233:02PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
11/29/20236:01AMPR Newswire (US)KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYNASDAQ:KZIAKazia Therapeutics Ltd
11/21/20236:30AMPR Newswire (US)KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
11/20/20233:39PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
11/20/20233:30PMPR Newswire (US)KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATIONNASDAQ:KZIAKazia Therapeutics Ltd
11/15/20238:13AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
11/15/20237:30AMPR Newswire (US)KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
11/10/20236:01AMPR Newswire (US)KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMANASDAQ:KZIAKazia Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:KZIA

Your Recent History

USOTC
SRMX
Saddle Ranch Media (PK)
NASDAQ
RNAZ
TransCode Therapeutics
USOTC
FMCC
Federal Home Loan Mortgage (QB)
NASDAQ
SEV
Sono Group NV
USOTC
FNMA
Fannie Mae (QB)
USOTC
IFUS
Impact Fusion (PK)
USOTC
AXXA
Exxe (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
ILST
International Star (PK)
USOTC
AFFU
Affluence (PK)
NASDAQ
COOP
Mr Cooper
NASDAQ
DJT
Trump Media and Technology
NASDAQ
AVXL
Anavex Life Sciences
COIN
SHIBUSD
SHIBA INU
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved